Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA · NASDAQ Global Select
-$0.10 today
Vol 2.20M · Avg 2.02M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+102.41%
Period High
$3.59
Period Low
$0.73
Latest
$1.51
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.84B
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$890.35M
Omeros Corporation
NASDAQ:OMER
$746.91M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$501.06M
Prothena Corporation plc
NASDAQ:PRTA
$463.33M
Autolus Therapeutics plc
NASDAQ:AUTL
$409.86M
Bicycle Therapeutics plc
NASDAQ:BCYC
$276.54M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$194.80M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
What is the latest NMRA filing?
The latest filing shown is 8-K dated Jun 15, 2026.
How many recent filings does NMRA have?
Intrinsic Alpha currently shows 20 recent filings for NMRA.
Explore More
Continue the stock analysis
Jump to another research area for this company.